Chronic pancreatitis

What changes during this transition

Chronic pancreatitis is progressive and irreversible — fibrosis and acinar destruction accumulate over years until the gland can no longer make enough digestive enzymes (exocrine insufficiency) or enough insulin from islet cells trapped in scarred parenchyma (type 3c, or pancreatogenic, diabetes). The TIGAR-O framework groups etiologies into Toxic-metabolic (alcohol drives 60-70% of cases worldwide; smoking is an independent accelerator; hypertriglyceridemia and hypercalcemia round out the toxic axis), Idiopathic, Genetic (PRSS1 hereditary pancreatitis, SPINK1, CFTR, CTRC, CASR), Autoimmune (type 1 IgG4-related; type 2 idiopathic duct-centric), Recurrent acute, and Obstructive (pancreas divisum, sphincter of Oddi dysfunction, tumors). Diagnosis combines clinical presentation with cross-sectional imaging — CT, MRCP (secretin-enhanced MRCP increasingly used for early-stage disease), endoscopic ultrasound graded against Rosemont criteria, fecal elastase-1 below 200 µg/g flagging exocrine insufficiency, serum trypsinogen, and genetic panels in early-onset or family-history cases. The care framework has five load-bearing pillars and one mandatory surveillance program. **Alcohol cessation is the single most important intervention** — continued drinking accelerates fibrosis, multiplies pain crises, drops pancreatic enzyme output further, and worsens the already-elevated pancreatic ductal adenocarcinoma risk. Smoking cessation runs parallel; tobacco is an independent fibrosis driver and a major PDAC risk multiplier, especially in PRSS1 hereditary disease. **Pain management** follows the WHO ladder with deliberate caution about opioid escalation (chronic pancreatitis carries one of the highest narcotic-dependence rates in chronic-pain populations); tricyclics and gabapentinoids address the neuropathic component; interventional options include celiac plexus block and thoracoscopic splanchnicectomy when medication-managed pain fails. **Pancreatic enzyme replacement therapy (PERT)** with pancrelipase (Creon, Zenpep, Pancreaze, Pertyze, Viokace) dosed with meals and snacks treats exocrine insufficiency — without adequate PERT, patients cannot absorb fat, fat-soluble vitamins, or adequate calories. **Fat-soluble vitamin replacement** (A, D, E, K) is monitored quarterly to annually; vitamin D deficiency drives the high osteoporosis rate seen in this population. **Insulin** treats type 3c diabetes once endocrine function fails — type 3c is brittle because alpha-cell (glucagon) loss accompanies beta-cell loss, so hypoglycemia is harder to counter-regulate. Endoscopic and surgical interventions handle structural disease: ERCP for ductal stones and strictures, pancreatic duct stenting, extracorporeal shock-wave lithotripsy for large stones; Puestow lateral pancreaticojejunostomy and Frey/Beger procedures for ductal dilation with head-of-pancreas inflammation; total pancreatectomy with islet auto-transplantation (TPIAT) as a definitive option in select centers for intractable pain. Pancreatic ductal adenocarcinoma surveillance is mandatory in hereditary pancreatitis (PRSS1 carriers begin imaging surveillance around age 40 per CAPS consortium guidance) and recommended in long-standing chronic pancreatitis with additional risk factors. Autoimmune pancreatitis type 1 — the IgG4-related disease form — is treated with corticosteroid induction, often with rituximab maintenance or relapse therapy; inebilizumab received FDA approval for IgG4-RD in 2024 and is changing the maintenance landscape (the same molecule referenced in batch 99 IgG4-RD substrate). Disease-specific resources include the National Pancreas Foundation, Mission: Cure (focused on hereditary pancreatitis), and the Pancreatic Cancer Action Network for surveillance and PDAC support. Peptides do not have an established place in this care framework. Community discussion sometimes elevates BPC-157 under a 'pancreas healing' or 'gut healing' frame, TB-500 under a 'fibrosis healing' frame, NMN under a general-aging mitochondrial frame, thymosin alpha-1 in IgG4-related autoimmune pancreatitis discussion, and KPV in mucosal anti-inflammatory framing. The substrate entries above exist so /ask can answer honestly when users raise these peptides — they do not endorse adding peptides to a chronic-pancreatitis regimen. Alcohol cessation, PERT optimization, fat-soluble vitamin repletion, type 3c diabetes management, and PDAC surveillance are where the actual disease-modifying leverage lives.